Greenwich LifeSciences, Inc.
General ticker "GLSI" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $284.2M (TTM average)
Greenwich LifeSciences, Inc. follows the US Stock Market performance with the rate: 18.0%.
Estimated limits based on current volatility of 5.3%: low 14.67$, high 16.33$
Factors to consider:
- Total employees count: 4 (-50.0%) as of 2025
- Top business risk factors: Clinical trial failure, Regulatory and compliance, Supply chain disruptions, Market competition, Pandemic risks
- Earnings for 6 months up through Q2 are below our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [10.19$, 24.87$]
- 2026-12-31 to 2027-12-31 estimated range: [8.44$, 21.20$]
Financial Metrics affecting the GLSI estimates:
- Positive: with PPE of -16.3 at the end of fiscal year the price was neutral
- Negative: negative Operating income
- Negative: negative Operating cash flow
- Negative: negative Net income
- Negative: Shareholder equity ratio, % of 5.72 <= 7.04
- Negative: negative Industry operating income (median)
- Negative: 0 < Industry inventory ratio change (median), % of 0
- Negative: Investing cash flow per share per price, % of 0 <= 2.08
- Negative: negative Industry operating cash flow (median)
Short-term GLSI quotes
Long-term GLSI plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | $0.00MM | $0.00MM | $0.00MM |
| Operating Expenses | $9.33MM | $16.01MM | $19.45MM |
| Operating Income | $-9.33MM | $-16.01MM | $-19.45MM |
| Non-Operating Income | $0.44MM | $0.22MM | $0.09MM |
| R&D Expense | $7.70MM | $12.95MM | $17.22MM |
| Income(Loss) | $-8.89MM | $-15.79MM | $-19.36MM |
| Net Income(Loss)* | $-8.89MM | $-15.79MM | $-19.36MM |
| Stockholders Equity | $6.70MM | $2.53MM | $0.35MM |
| Assets | $6.99MM | $4.09MM | $6.18MM |
| Operating Cash Flow | $-6.48MM | $-7.27MM | $-9.91MM |
| Capital expenditure | $0.00MM | $0.00MM | $0.00MM |
| Financing Cash Flow | $0.00MM | $4.37MM | $12.00MM |
| Earnings Per Share** | $-0.69 | $-1.21 | $-1.43 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.